Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.

The same trend was also observed for NNMT protein expression in cohort 1, although the difference did not reach statistical significance (HR = 2.0, 95% CI: 0.7–6.0), likely due to the limited number of samples in this analysis (Figure 1G ).

also in 111,027 other papers